Heart Initiative, the sponsor of the STRONG-HF (Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP testinG, of Heart Failure therapies) study, announced the premature termination of the trial.
News | Cardiovascular Clinical Studies
STRONG-HF Study in Patients Admitted for Acute Heart Failure (HF) Terminated Early for Superior Efficacy

October 14, 2022 — Heart Initiative, the sponsor of the STRONG-HF (Safety, Tolerability and efficacy of Rapid ...

Home October 14, 2022
Home
The data, collected during the transition from intravenous (IV) to oral levosimendan in the open-label extension (OLE) of the HELP (Hemodynamic Evaluation of Levosimendan in PH-HFpEF) trial, were presented at the Heart Failure Society of America (HFSA) Scientific Sessions 2022
News | Heart Failure
Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

October 13, 2022 — Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing, and ...

Home October 13, 2022
Home
the U.S. Patent and Trademark Office has issued to the University of Iowa Research Foundation ("UIRF") U.S. Patent No. 11,414,704 titled COMPOSITIONS AND METHODS FOR DETECTING PREDISPOSITION TO CARDIOVASCULAR DISEASE, which is exclusively licensed to the Company from UIRF
News | Heart Failure
Cardio Diagnostics Announces Issuance of U.S. Patent for Compositions and Methods for Detecting Predisposition to Cardiovascular Disease

October 13, 2022 — Cardio Diagnostics, Inc. , a pioneering precision cardiovascular testing company, announced that the ...

Home October 13, 2022
Home
Zach Williams wanted to be a cancer researcher, but quick success in another area refocused his research on cardiovascular science. He was awarded a National Institutes of Health grant to fund his research for two years. Image courtesy of Clayton Metz/Virginia Tech.
News | Heart Failure
Virginia Tech Graduate Student Earns NIH Support to Explore Promising Heart Finding

October 13, 2022 — Zach Williams thought he’d become a cancer researcher when he joined Virginia Tech’s Translational ...

Home October 13, 2022
Home
Videos | TCT
VIDEO: 3-Year Follow-up of the SYMPLICITY HTN-3 Trial

At TCT 2022, Deepak Bhatt, MD, MPh, Executive Director of Interventional Cardiovascular Programs, Brigham and Women's ...

Home October 13, 2022
Home
The Delphi study results show Philips’ integrated echocardiography solution provides the tools required for baseline risk stratification and monitoring of cardio-oncology patients as recommended by the latest European Society of Cardiology (ESC) guidelines
News | Heart Failure
Panel of Experts Highlights Clinical and Operational Benefits of Philips’ Integrated Echocardiography Solution

October 12, 2022 — Following the recent European Society of Cardiology (ESC) Congress in Barcelona, Spain last month ...

Home October 12, 2022
Home
Study investigates metformin and other candidate drugs through a network medicine approach
News | Heart Failure
Cleveland Clinic Researchers Identify Diabetes Drug Metformin as Potential Atrial Fibrillation Treatment in Collaborative Research

October 12, 2022 — Cleveland Clinic researchers have identified a common diabetes medication, metformin, as a possible ...

Home October 12, 2022
Home
Renowned Stanford Cardiologist Brings Deep Clinical, Research, and Industry Expertise to Executive Team
News | Cardiovascular Business
HeartBeam Names Peter J. Fitzgerald, MD, PhD, as Chief Medical Officer

October 12, 2022 — HeartBeam, Inc., a cardiac technology company that has developed the first and only 3D-vector ECG ...

Home October 12, 2022
Home
Share Images Automatically, Instantly, and Securely
Sponsored Content | Whitepapers | Archive Cloud Storage
Strategic Planning for Imaging in the Cloud

Change Healthcare’s cloud-native archiving, viewing, and image-sharing solutions can help improve efficiencies in ...

Home October 11, 2022
Home
Results now available for the first 10 patients being treated with the ELANA open heart bypass solution as part of a SAFE-CAB trial.
News | Cardiovascular Clinical Studies
ELANA Heart Bypass Solution Shows Promising Preliminary Results in First-in-Human Trials

October 11, 2022 — The preliminary results of the first-in-human (FIH) trials for the innovative ELANA Heart Bypass ...

Home October 11, 2022
Home
Researchers from the University of Minnesota Medical School found that patients with certain features on magnetic resonance imaging (MRI) of the heart are at much higher risk for cardiac sarcoidosis-related adverse outcomes.
News | Cardiac Imaging
Identifying Patients with Sarcoidosis at Risk for Bad Cardiac Outcomes

October 11, 2022 — Researchers from the University of Minnesota Medical School found that patients with certain features ...

Home October 11, 2022
Home
Grant Proceeds Will Support Pre-Clinical Studies
News | Stents Bioresorbable
Efemoral Medical Awarded Phase II SBIR Grant from NIH to Advance Treatment for Peripheral Artery Disease

October 11, 2022 — Efemoral Medical, developer of advanced interventional bioresorbable therapies, announced that it has ...

Home October 11, 2022
Home
Kyle Walsh, MD
News | Stroke
Identifying How Inflammation Affects Stroke Recovery

October 7, 2022 — A new research grant will enable University of Cincinnati researchers to learn more about how ...

Home October 07, 2022
Home
Ultromics, a digital health technology company pioneering the development of transformative heart failure diagnostics, has joined as a full partner The Accelerating Medicines Partnership® Heart Failure (AMP HF) including the National Institutes of Health (NIH) and the National Heart Lung and Blood Institute (NHLBI), managed by the Foundation for the National Institutes of Health (FNIH).
News | Heart Failure
Ultromics joins FNIH Partnership to Transform Heart Failure Detection

October 7, 2022 — Ultromics, a digital health technology company pioneering the development of transformative heart ...

Home October 07, 2022
Home
This is the first study to investigate the safety and tolerability of NR in a randomized, placebo-controlled trial of patients with heart failure, marking a milestone for future clinical research
News | Heart Failure
ChromaDex Shares Promising Findings from Clinical Study Showcasing ​​the Safety and Tolerability of Nicotinamide Riboside (NR) in Heart Failure With Reduced Ejection Fraction

October 7, 2022 — ChromaDex Corp. announced promising findings from a clinical study, as reported in the peer-reviewed ...

Home October 07, 2022
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now